The plasma concentration of advanced oxidation protein products and arterial stiffness in apparently healthy adults

Free Radical Research

Volumn 41, Issue 6, 2007, Pages 645-649

  Wykretowicz, Andrzej ^a   Adamska, Karolina ^a   Krauze, Tomasz ^a   Guzik, Przemyslaw ^a   Szczepanik, Adam ^a   Rutkowska, Agnieszka ^a   Wysoki, Henryk ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Advanced oxidation protein products; Arterial stiffness; Oxidative stress; Plasma concentration

Indexed keywords

ADVANCED OXIDATION PROTEIN PRODUCTS; BIOLOGICAL MARKER; UNCLASSIFIED DRUG;

ADULT; ARTERY DISEASE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY FAT; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MULTIPLE REGRESSION; OXIDATIVE STRESS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL;

ADIPOSE TISSUE; ADULT; BIOLOGICAL MARKERS; BLOOD PRESSURE; BLOOD PROTEINS; BODY MASS INDEX; FEMALE; HUMANS; MALE; MIDDLE AGED; OXIDATION-REDUCTION; OXIDATIVE STRESS; VASCULAR RESISTANCE;

EID: 34249815512     PISSN: 10715762     EISSN: 10292470     Source Type: Journal    
DOI: 10.1080/10715760701236741     Document Type: Article

References (33)

1. Lakatta, EG and Levy, D. (2003) Arterial and cardiac aging: Major shareholders in cardiovascular disease enterprises: Part I: Aging arteries: A "set up" for vascular disease. Circulation, 107, pp. 139-146.
2. De Angelis, L., Millasseau, SC, Smith, A., Viberti, GC, Jones, RH, Ritter, JM and Chowienczyk, PJ (2004) Sex differences in age-related stiffening of the aorta in subjects with type 2 diabetes. Hypertension, 44, pp. 67-71.
3. Stewart, AD, Jiang, B., Millasseau, SC, Ritter, JM and Chowienczyk, PJ (2006) Acute reduction of blood pressure by nitroglycerin does not normalize large artery stiffness in essential hypertension. Hypertension, 48, pp. 404-410.
4. Whincup, PH, Gilg, JA, Donald, AE, Katterhorn, M., Oliver, C., Cook, DG and Deanfield, JE (2005) Arterial distensibility in adolescents: The influence of adiposity, the metabolic syndrome, and classic risk factors. Circulation, 112, pp. 1789-1797.
5. Guerin, AP, Blacher, J., Pannier, B., Marchais, SJ, Safar, ME and London, G. (2001) Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation, 103, pp. 987-992.
6. Yasmin, McEniery, CM, Wallace, S., Mackenzie, IS, Cockcroft, JR and Wilkinson, IB (2004) C-reactive protein is associated with arterial stiffness in apparently healthy individuals. Arterioscler Thromb Vasc Biol, 24, pp. 969-974.
7. Boutouyrie, P., Tropeano, AI, Asmar, R., Gautier, I., Benetos, A., Lacolley, P. and Laurent, S. (2002) Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: A longitudinal study. Hypertension, 39, pp. 10-15.
8. Meaume, S., Benetos, A., Henry, OF, Rudnichi, A. and Safar, ME (2001) Aortic pulse wave velocity predicts cardiovascular mortality in subjects 70 years of age. Arterioscler Thromb Vasc Biol, 21, pp. 2046-2050.
9. Millasseau, SC, Kelly, RP, Ritter, JM and Chowienczyk, PJ (2002) Determination of age-related increases in large artery stiffness by digital pulse contour analysis. Clin Sci, 103, pp. 371-377.
10. Millasseau, SC, Kelly, RP, Ritter, JM and Chowienczyk, PJ (2003) The vascular impact of aging and vasoactive drugs: Comparison of two digital volume measurements. Am J Hypertens, 16, pp. 467-472.
11. Millasseau, SC, Ritter, JM, Takazawa, K. and Chowienczyk, PJ (2006) Contour analysis of the photoplethysmographic pulse measured at the finger. J Hypertens, 24, pp. 1449-1456.
12. Kalra, L., Rambaran, C., Iveson, E., Chowienczyk, PJ, Hambleton, I., Ritter, JM, Shah, A., Wilks, R. and Forrester, T. (2006) The role of inheritance and environment in predisposition to vascular disease in people of African descent. J Am Coll Cardiol, 47, pp. 1126-1133.
13. Harper, ME, Bevilacqua, L., Hagopian, K., Weindruch, R. and Ramsey, JJ (2004) Ageing, oxidative stress, and mitochondrial uncoupling. Acta Physiol Scand, 182, pp. 321-331.
14. Baynes, JW (1991) Role of oxidative stress in development of complications in diabetes. Diabetes, 40, pp. 405-412.
15. Landmesser, U., Cai, H., Dikalov, S., McCann, L., Hwang, J., Holland, S. and Harrison, D. (2002) Role of p47(phox) in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension, 40, pp. 511-515.
16. Loeckie, L., De Zwart, LL, Meerman, JHN, Commandeur, JNM and Vermeulen, NPE (1999) Biomarkers of free radical damage applications in experimental animals and in humans. Free Radic Biol Med, 26, pp. 202-226.
17. Clapp, BR, Hirschfield, GM, Storry, C., Gallimore, JR, Stidwill, P., Singer, M., Deanfield, JE, MacAllister, RJ, Pepys, MB, Vallance, P. and Hingorani, AD (2005) Inflammation and endothelial function: Direct vascular effects of human C-reactive protein on nitric oxide bioavailability. Circulation, 111, pp. 1530-1536.
18. Ridker, PM, Rifai, N., Pfeffer, MA, Sacks, FM, Moye, LA, Goldman, S., Flaker, GC and Braunwald, E. (1998) Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events (CARE) investigators. Circulation, 98, pp. 839-844.
19. Ridker, PM, Rifai, N., Rose, L., Buring, JE and Cook, NR (2002) Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med, 347, pp. 1557-1565.
20. Witko-Sarsat, V., Friedlander, M., Capeillere-Blandin, C., Nguyen-Khoa, T., Nguyen, AT, Zingraff, J., Jungers, P. and Descamps-Latscha, B. (1996) Advanced oxidation protein products as novel marker of oxidative stress in uremia. Kidney Int, 49, pp. 1304-1313.
21. Witko-Sarsat, V., Friedlander, M., Nguyen-Khoa, T., Capeillere-Blandin, C., Nguyen, AT, Canteloup, P., Dayer, JM, Jungers, P. and Descamps-Latscha, B. (1998) Advanced oxidation protein products as native mediators of inflammation and monocyte activation in chronic renal failure. J Immunol, 161, pp. 2524-2532.
22. Kanada, H., Taguchi, J., Ogasawara, K., Lizawa, T. and Ohno, M. (2002) Increased level of advanced oxidation protein products in patients with coronary artery disease. Atherosclerosis, 162, pp. 221-225.
23. Chiu-Braga, YY, Hayashi, SY, Schafranski, M. and Messias-Reason, IJT (2006) Further evidence of inflammation in chronic rheumatic valve disease (CRVD): High levels of advanced oxidation protein products (AOPP) and high sensitive C-reactive protein (hs-CRP). Int J Cardiol, 109, pp. 275-276.
24. Kalousova, M., Krha, J. and Zima, T. (2002) Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiol Res, 51, pp. 597-604.
25. Kalousova, M., Zima, T., Teras, V., Skra, J. and Stipek, S. (2002) Determination of advanced glycation end-products and advanced oxidation protein products. Klin Biochem Metab, 10, pp. 11-16.
26. Wildman, RP, Mackey, RH, Bostom, A., Thompson, T. and Sutton-Tyrrell, K. (2003) Measures of obesity are associated with vascular stiffness in young and older adults. Hypertension, 42, pp. 468-473.
27. Liao, D., Arnett, DK, Tyroler, HA, Riley, WA, Chambless, LE, Szklo, M. and Heiss, G. (1999) Arterial stiffness and the development of hypertension. The ARIC study. Hypertension, 34, pp. 201-206.
28. Roman, MJ, Devereux, RB, Schwartz, JE, Lockshin, MD, Paget, SA, Davis, A., Crow, MK, Sammaritano, L., Levine, DM, Shankar, BA, Moeller, E. and Salmon, JE (2005) Arterial stiffness in chronic inflammatory diseases. Hypertension, 46, pp. 194-199.
29. Descamps-Latscha, B. and Witko-Sarsat, V. (2001) Importance of oxidatively modified proteins in chronic renal failure. Kidney Int, 59, pp. S108-S113.
30. Wykretowicz, A., Guzik, P., Kasinowski, R., Krauze, T., Bartkowiak, G., Dziarmaga, M. and Wysoki, H. (2005) Augmentation index, pulse pressure amplification and superoxide anion production in patients with coronary artery disease. Int J Cardiol, 99, pp. 289-294.
31. Chen, JY, Tsai, WC, Lin, CC, Huang, YY, Hsu, CH, Liu, PY and Chen, JH (2005) Stiffness index derived from digital volume pulse as a marker of target organ damage in untreated hypertension. Blood Press, 14, pp. 233-237.
32. Drüeke, T., Witko-Sarsat, V., Massy, Z., Descamps-Latscha, B., Guerin, AP, Marchais, SJ, Gausson, V. and London, GM (2002) Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation, 106, pp. 2212-2217.
33. Descamps-Latscha, B., Drüeke, T. and Witko-Sarsat, V. (2001) Dialysis-induced oxidative stress: Biological aspects, clinical consequences and therapy. Semin Dial, 14, pp. 193-199.